SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Iovance shares fall more than 32% after updated lung cancer trial results

Shares fell more than 32% on Thursday, putting the stock on track for its worst session since May 2025. The sell-off followed updated lung cancer trial results.

IOVA
SquawkNews Desk

Shares of Iovance Biotherapeutics (IOVA) crashed more than 32% on Thursday, putting the stock on track for its worst session since May 2025, after the biotech firm posted updated lung cancer trial results.The sell-off also pushed IOVA stock below its 50-day moving average (50-DMA) for the first tim…

Related stories

Starbucks Reports Q4 Results, Announces $1 Billion Buyback and FY2027 Guidance Starbucks reported fiscal fourth-quarter non-GAAP EPS of $0.80 on revenue of $9.14 billion. Global comparable sales rose 7.2%, and operating margin expanded to 14.0% from 9.4% a ye H impact | EQUITY | Oct 30, 2026, 11:02 PM UTC Intel Shares Plunge Nearly 30% on Wall Street Intel shares fell nearly 30% despite revenue rising 21% in the third quarter of 2026. H impact | EQUITY | Oct 30, 2026, 10:41 PM UTC Big Tech Shareholder Returns Hit 15-Year Low as AI Spending Surges Microsoft, Alphabet, Amazon, Meta and Oracle returned 9.3 M impact | EQUITY | Oct 30, 2026, 10:25 PM UTC Microsoft and BMW Introduce Voluntary Employee Exit Offers Microsoft and BMW have introduced voluntary exit programmes, according to the report. New research suggests financial incentives for employees to leave could help companies reshape M impact | EQUITY | Oct 30, 2026, 10:04 PM UTC S&P Global Lowers Meta Outlook to Negative on AI Spending S&P Global lowered Meta’s outlook to negative, citing AI spending and cash-flow concerns. M impact | EQUITY | Oct 30, 2026, 09:50 PM UTC Partnership Acquires Site for Morgan Stanley’s Planned Dallas Tower A new partnership acquired the Uptown Dallas site where Morgan Stanley plans to build a billion-dollar tower. M impact | EQUITY | Oct 30, 2026, 09:46 PM UTC